Academic Public Private Partnership Program (Ap4) Planning Grant

The summary for the Academic Public Private Partnership Program (Ap4) Planning Grant grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Academic Public Private Partnership Program (Ap4) Planning Grant: The Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) invites academic cancer researchers to participate in the Academic Public Private Partnership Program (AP4). The purpose of the AP4 initiative is to provide support for the formation of new partnerships or significant expansions of existing partnerships among academia, industry, non-profit institutions, and government entities. The partnerships will conduct novel cancer therapeutic, prevention, diagnostic, and imaging intervention-directed research. The goal of the research will be to speed the translation of newly discovered cancer interventions to clinical trials. The NCI is assisting the formation of these partnerships by offering to academic and non-profit researchers a one-year planning grant, which is the subject of this RFA. The planning grant will be utilized by the academic or non-profit cancer researcher to study the feasibility of developing the pharmaceutical/non-profit/academic interaction necessary to establish and support a partnership, to hold a meeting of potential partners and select research projects for the potential AP4 Center. The research focus of these partnerships should take advantage of the latest discovery and development technologies and include projects which focus on cancers that meet the definition of orphan disease (those that affect less than 200,000 people per year in the United States) using a multidisciplinary approach. Biologically defined subsets of more common tumor types could also be defined as having "orphan" status. The research will occur at the AP4 Center with the advice and intellectual and financial support of industrial, academic, non-profit institute, other government partners and the NCI. The goal of the research conducted in the AP4 center is to generate novel interventions, development of which for human clinical trials will be supported by other financial resources. The impetus behind the creation of such a program is to promote public- private partnerships that will advance our basic knowledge of the molecular biological events that lead to cancer, and to apply that knowledge to the development of novel cancer interventions. The strategy addresses an important issue: how to bring together the necessary multidisciplinary expertise to discover new, more effective treatment, diagnostic, and prevention interventions for cancer, and shorten the time required to bring these new interventions to clinical trials. A number of recent NCI initiatives aim to support key steps in the intervention discovery and development process (see: Rapid Access to NCI Discovery Resources (R-A-N-D); Rapid Access to Intervention Development (RAID); Flexible System to Advance Innovative Research (FLAIR); and Molecular Target Drug Discovery grants (MTDDs)at: http://dtp.nci.nih.gov). The above initiatives provide assistance for the most part to individual researchers. The present initiative has a very different organizational focus. We wish to bring together the basic research skills inherent in the academic institutions, the scientific expertise of industry, the interests of disease-oriented charities and non-profit groups, and the administrative support, resources, and years of discovery and development expertise of the DTP, DCTD, NCI.